Mutations in PI3K catalytic subunit genes, especially p110α (PIK3CA), were frequently identified in prostate cancer with concurrent PIK3CA mutation and loss of phosphatase and tensin homolog (PTEN) accelerating tumorigenesis and promoting CRPC in mouse models [13]. This evidence concerns the gene PIK3CD and prostate cancer.